Chlamydia Tests – Medical Devices Pipeline Assessment, 2017

Chlamydia Tests use a sample of body fluid or urine to see whether chlamydia bacteria are present and causing an infection. It is used to screen for, diagnose, and verify successful treatment of infections caused by the bacteria Chlamydia trachomatis. GlobalData's Medical Devices sector report, “Chlamydia Tests – Medical Devices Pipeline Assessment, 2017" provides comprehensive information about the Chlamydia Tests pipeline products with comparative analysis of the products at various stages of development and information about the clinical trials which are in progress.

The Chlamydia Tests Pipeline Assessment report provides key information and data related to:

Extensive coverage of the Chlamydia Tests under development

Review details of major pipeline products which include product description, licensing and collaboration details and other developmental activities including pipeline territories, regulatory paths and estimated approval dates

Reviews of major players involved in the pipeline product development.

Provides key clinical trial data related to ongoing clinical trials such as trial phase, trial status, trial start and end dates, and, the number of trials of the major Chlamydia Tests pipeline products.

Review of Recent Developments in the segment / industry

The Chlamydia Tests Pipeline Assessment report enables you to:

Access significant competitor information, analysis, and insights to improve your R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of Chlamydia Tests under development

Formulate market-entry and market expansion strategies

Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data in relation to the equipment type.

The GlobalData Differentiation

This report is prepared using data sourced from in-house databases, secondary and primary research by GlobalData's team of industry experts.

The data and analysis within this report are driven by GlobalData Medical Intelligence Center (GDMIC) database. GDMIC gives you the key information required to drive sales, investment and deal-making activity in your business. It includes the following:

• 15,000+ data tables showing market size across more than 780 medical equipment segments and 39 countries, from 2009 and forecast to 2023

• 4,500+ industry-leading analysis and procedure reports covering growing sectors, market trends, investment opportunities and competitive landscape

• 56,000+ medical equipment company profiles

• 4,300+ company profiles of medical equipment manufacturers in China and India

• 2,000+ company profiles of medical equipment manufacturers in Japan

• 825+ companies’ revenue splits and market shares

• 1,900+ quarterly and annual medical equipment company financials

• 940+ medical equipment company SWOTs

• 21,500+ pipeline product profiles

• 34,500+ marketed product profiles

• 36,000+ clinical trials

• 36,500+ trial investigators

• 5,400+ reports on companies with products in development

• 33,000+ deals in the medical equipment industry

• 1,300+ surgical and diagnostic procedures by therapy area

• 50+ key healthcare indicators by country

For more information or to receive a free demonstration of the service, please visit:

https://medical.globaldata.com/home.aspx

Custom Requirements

Contact us to discuss the areas of your business where you need external input, and we will work with you to identify the strongest way forward to meet your needs.

Scope

NA

Companies mentioned

Beckman Coulter Inc

bioMerieux S.A.

Boditech Med Inc

DiaSorin S.p.A

Ellume

Genome Diagnostics Pvt. Ltd.

Molbio Diagnostics Pvt. Ltd.

ProCelo AS

Queensland University of Technology

Quidel Corp

Sansure Biotech Inc

Table of Contents

1 Table of Contents 2

1.1 List of Tables 4

1.2 List of Figures 4

2 Introduction 5

2.1 Chlamydia Tests Overview 5

3 Products under Development 6

3.1 Chlamydia Tests – Pipeline Products by Stage of Development 6

3.2 Chlamydia Tests – Pipeline Products by Territory 7

3.3 Chlamydia Tests – Pipeline Products by Regulatory Path 8

3.4 Chlamydia Tests – Pipeline Products by Estimated Approval Date 9

4 Chlamydia Tests – Pipeline Products under Development by Companies 10

4.1 Chlamydia Tests Companies – Pipeline Products by Stage of Development 10

4.2 Chlamydia Tests – Pipeline Products by Stage of Development 11

5 Chlamydia Tests Companies and Product Overview 12

5.1 Beckman Coulter Inc Company Overview 12

5.1.1 Beckman Coulter Inc Pipeline Products & Ongoing Clinical Trials Overview 12

5.2 bioMerieux S.A. Company Overview 13

5.2.1 bioMerieux S.A. Pipeline Products & Ongoing Clinical Trials Overview 13

5.3 Boditech Med Inc Company Overview 14

5.3.1 Boditech Med Inc Pipeline Products & Ongoing Clinical Trials Overview 14

5.4 DiaSorin S.p.A Company Overview 15

5.4.1 DiaSorin S.p.A Pipeline Products & Ongoing Clinical Trials Overview 15

5.5 Ellume Company Overview 18

5.5.1 Ellume Pipeline Products & Ongoing Clinical Trials Overview 18

5.6 Genome Diagnostics Pvt. Ltd. Company Overview 19

5.6.1 Genome Diagnostics Pvt. Ltd. Pipeline Products & Ongoing Clinical Trials Overview 19

5.7 Molbio Diagnostics Pvt. Ltd. Company Overview 20

5.7.1 Molbio Diagnostics Pvt. Ltd. Pipeline Products & Ongoing Clinical Trials Overview 20

5.8 ProCelo AS Company Overview 21

5.8.1 ProCelo AS Pipeline Products & Ongoing Clinical Trials Overview 21

5.9 Queensland University of Technology Company Overview 22

5.9.1 Queensland University of Technology Pipeline Products & Ongoing Clinical Trials Overview 22

5.10 Quidel Corp Company Overview 23

5.10.1 Quidel Corp Pipeline Products & Ongoing Clinical Trials Overview 23

5.11 Sansure Biotech Inc Company Overview 24

5.11.1 Sansure Biotech Inc Pipeline Products & Ongoing Clinical Trials Overview 24

6 Chlamydia Tests – Recent Developments 25

6.1 May 16, 2017: Charles J. Dockendorff Elected to Hologic Board of Directors 25

6.2 May 16, 2017: Akers Biosciences Announces Q1 2017 Earnings 25

6.3 May 10, 2017: Hologic Announces Financial Results for Second Quarter of Fiscal 2017 27

6.4 May 10, 2017: Meridian Bioscience Engages Korn Ferry to Conduct CEO Search as John A. Kraeutler Announces Plans to Retire 28

6.5 May 02, 2017: BD Announces Results For 2017 Second Fiscal Quarter 29

6.6 Apr 27, 2017: Meridian Bioscience Reports Second Quarter 2017 Operating Results 31

6.7 Apr 24, 2017: Quidel Reports First Quarter 2017 Financial Results 33

6.8 Apr 23, 2017: BD Announces Appointment Of Tom Polen As President 34

6.9 Apr 20, 2017: bioMerieux – First-Quarter 2017 Business Review 34

6.10 Apr 11, 2017: Akers Bioscience: Financial Results for the Year Ended December 31, 2016 37

6.11 Apr 11, 2017: Akers Biosciences Reports Earnings for Fiscal Year 2016 38

6.12 Mar 30, 2017: Akers Biosciences Reports Preliminary Unaudited Earnings Highlights for Fiscal Year 2016 42

6.13 Mar 28, 2017: BD Announces Success of Helping Build Healthy Communities Program, Launches New Effort Focused on Medication Therapy Management 44

6.14 Mar 21, 2017: Retractable Technologies Announces Litigation Updates 45

6.15 Mar 09, 2017: Alere Provides Update on Arriva Medical 45

6.16 Feb 08, 2017: Quidel Reports Fourth Quarter and Full Year 2016 Financial Results 45

6.17 Feb 02, 2017: BD Announces Results For 2017 First Fiscal Quarter 47

6.18 Feb 01, 2017: Hologic Announces Financial Results for First Quarter of Fiscal 2017 48

6.19 Jan 23, 2017: Quidel Announces Modification of Revenue Reporting Categories 50

6.20 Jan 19, 2017: bioMerieux – Fourth-Quarter 2016 Business Review 50

6.21 Jan 13, 2017: ProteoMediX receives ISO 13485:2012 Certification 52

6.22 Jan 06, 2017: Quidel Announces Preliminary Revenue for Fourth Quarter 2016 53

6.23 Jan 04, 2017: Hologic Appoints President of EMEA and Canada, Completing International Leadership Team 53

6.24 Jan 04, 2017: Alere Laboratory Receives ABFT Accreditation 54

6.25 Jan 04, 2017: Alere Provides Update on Arriva Medical 54

6.26 Dec 28, 2016: Alere Provides Update on Arriva Medical 55

6.27 Dec 16, 2016: Amy Wendell Elected to Hologic Board of Directors 56

6.28 Dec 14, 2016: Beckman Coulter appoints IT Product Manager for Northern Europe 56

6.29 Dec 08, 2016: Khang & Khang Announces Securities Class Action Lawsuit against Alere and Reminds Investors with Losses to Contact the Firm 57

6.30 Dec 07, 2016: Abbott Seeks To Terminate Alere Acquisition 57

6.31 Nov 14, 2016: Akers Biosciences Announces Q3 Earnings 57

6.32 Nov 10, 2016: Meridian Bioscience Reports Fourth Quarter and Full-Year Operating Results 59

6.33 Nov 10, 2016: Diasorin Group Reports Continued Growth In Revenues And Profitability In The Third Quarter 2016 61

6.34 Nov 07, 2016: Pierre Boulud appointed Corporate Vice Presidentof the Asia Pacific region at bioMerieux 62

6.35 Nov 04, 2016: Alere Reports Third Quarter 2016 Financial Results 62

6.36 Nov 03, 2016: BD Announces Results For 2016 Fourth Fiscal Quarter And Full Year; Provides Fiscal 2017 Guidance 63

6.37 Nov 02, 2016: Hologic Announces Financial Results for Fourth Quarter of Fiscal 2016 65

6.38 Oct 26, 2016: Quidel Reports Third Quarter 2016 Financial Results 66

6.39 Oct 20, 2016: bioMerieux-Business Review for the nine months ended September 30, 2016 68

6.40 Oct 18, 2016: Meridian Bioscience Comments on Preliminary Fiscal 2016 Operating Results and Provides Fiscal 2017 Revenue and Earnings Guidance 70

6.41 Oct 03, 2016: Bioline is Certified to the ISO 13485 Quality Standard 72

6.42 Sep 06, 2016: Alere Reports Second Quarter 2016 Financial Results 72

6.43 Aug 31, 2016: bioMerieux – First-Half 2016 Results 73

6.44 Aug 17, 2016: Alere Reports First Quarter 2016 Financial Results 77

6.45 Aug 11, 2016: Akers Biosciences Announces H1 and Q2 2016 Earnings 78

6.46 Aug 08, 2016: Alere Files Form 10-K, Reports Fourth Quarter and Full Year 2015 Financial Results 79

6.47 Aug 04, 2016: BD Announces Results For 2016 Third Fiscal Quarter 81

6.48 Aug 04, 2016: Diasorin Group Revenues And EBITDA Reached Record highs In the Second Quarter 2016 83

6.49 Jul 28, 2016: BD Names R. Andrew Eckert To Board Of Directors 87

6.50 Jul 28, 2016: Cepheid Reports Second Quarter 2016 Results 87

6.51 Jul 28, 2016: Meridian Bioscience Reports Third Quarter 2016 Operating Results, Declares Regular Cash Dividend, and Updates Fiscal 2016 Guidance 88

6.52 Jul 27, 2016: Hologic Announces Financial Results for Third Quarter of Fiscal 2016 90

6.53 Jul 27, 2016: Quidel Reports Second Quarter 2016 Financial Results 92

6.54 Jul 18, 2016: bioMerieux – Second-Quarter 2016 Business Review 93

7 Appendix 97

7.1 Methodology 97

7.2 About GlobalData 100

7.3 Contact Us 100

7.4 Disclaimer 100

List of Tables

Table 1: Chlamydia Tests – Pipeline Products by Stage of Development 6

Table 2: Chlamydia Tests – Pipeline Products by Territory 7

Table 3: Chlamydia Tests – Pipeline Products by Regulatory Path 8

Table 4: Chlamydia Tests – Pipeline Products by Estimated Approval Date 9

Table 5: Chlamydia Companies – Pipeline Products by Stage of Development 10

Table 6: Chlamydia Tests – Pipeline Products by Stage of Development 11

Table 7: Beckman Coulter Inc Pipeline Products & Ongoing Clinical Trials Overview 12

Table 10: bioMerieux S.A. Pipeline Products & Ongoing Clinical Trials Overview 13

Table 13: Boditech Med Inc Pipeline Products & Ongoing Clinical Trials Overview 14

Table 16: DiaSorin S.p.A Pipeline Products & Ongoing Clinical Trials Overview 15

Table 23: Ellume Pipeline Products & Ongoing Clinical Trials Overview 18

Table 26: Genome Diagnostics Pvt. Ltd. Pipeline Products & Ongoing Clinical Trials Overview 19

Table 29: Molbio Diagnostics Pvt. Ltd. Pipeline Products & Ongoing Clinical Trials Overview 20

Table 32: ProCelo AS Pipeline Products & Ongoing Clinical Trials Overview 21

Table 35: Queensland University of Technology Pipeline Products & Ongoing Clinical Trials Overview 22

Table 38: Quidel Corp Pipeline Products & Ongoing Clinical Trials Overview 23

Table 41: Sansure Biotech Inc Pipeline Products & Ongoing Clinical Trials Overview 24

Table 44: Glossary 99

List of Figures

Figure 1: Chlamydia Tests – Pipeline Products by Stage of Development 6

Figure 2: Chlamydia – Pipeline Products by Territory 7

Figure 3: Chlamydia Tests – Pipeline Products by Regulatory Path 8

Figure 4: Chlamydia Tests – Pipeline Products by Estimated Approval Date 9

    Pricing

Discounts available for multiple purchases.

reportstore@globaldata.com
+44 20 7947 2745

Join our mailing list

Saved reports